Biomarker-Driven Lung Cancer | Clinical

FDA Grants Regular Approval to Capmatinib for Patients With METex14-Positive NSCLC

August 11, 2022

An accelerated approval by the FDA for capmatinib has be converted to a regular approval based on new data from adults patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping.

Survival Benefit Seen With Frontline Tremelimumab/Durvalumab/Chemo in Some mNSCLC

August 09, 2022

The combination of tremelimumab plus durvalumab and chemotherapy in the first-line elicited survival benefit in patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations.

Promising Safety With Sotorasib Plus Pembrolizumab for KRAS G12C+ NSCLC

August 07, 2022

Sotorasib plus either pembrolizumab or atezolizumab revealed promising efficacy and relatively low rates of hepatotoxicity with a lead-in dosing strategy in patients with KRAS G12C–positive non–small cell lung cancer.